

Taiwan's Bora Pharmaceuticals makes strategic investment into Tanvex for global biomanufacturing services

28 August 2024 | News

Bora Pharmaceuticals will closely collaborate with Tanvex to leverage its global CDMO operations and capabilities



Taiwan-based Bora Pharmaceuticals Co. has announced that its Board of Directors has approved a strategic investment into Tanvex Biopharma Co., whereby Bora Biologics, a wholly owned subsidiary of Bora and specialist large molecule CDMO (contract development and manufacturing organisation), and Tanvex will combine their biomanufacturing facilities to create a global solution for biologics development and supply.

The investment will bring together Bora's extensive CDMO capabilities and total service culture with Tanvex's scale, development expertise and US FDA-approved commercial-scale facility in San Diego, California, and, upon completion, the appointment of Bobby Sheng, Chairman and CEO of the Bora Group, as Chairman of the merged organisation.

Upon completion of the transaction, which is expected in Q1 of 2025, Bora will hold approximately 30.5% of Tanvex's total outstanding shares based on current shareholding structure, becoming the single largest shareholder of Tanvex.

Bora Pharmaceuticals will closely collaborate with Tanvex to leverage its global CDMO operations and capabilities to provide comprehensive solutions to biologics customers, including Bora's new fill/finish capabilities in Maryland, USA. Tanvex has created a strong biologics development and manufacturing operations in both USA and Taiwan. Combined, these capabilities offer a global development and manufacturing platform to biologics customers both in US and Asia. Tanvex brings over 100,000 sq. ft. of biomanufacturing space and 1,000 litre bioreactors, which complement Bora's 500-litre bioreactors to provide a scalable service offering.

This strategic investment marks Bora Group's third major announcement in 2024 following its recent acquisition of Upsher Smith's extensive small molecule operations and the acquisition of a sterile injectable manufacturing facility in Baltimore-Camden, Maryland, which strengthened Bora's fill/finish capabilities, which are essential for large molecule CDMO services and will help provide an integrated solution to the new customers.